BTK and diffuse large B-cell lymphoma: Recent studies have demonstrated that treatment regimens incorporating BTK inhibitors, such as zanubrutinib, can safely and effectively treat both systemic high-risk DLBCL and primary central nervous system lymphoma (PCNSL) (48).